Abstract
Purpose
To compare the clinical effectiveness of 1% Prednisolone acetate ophthalmic solution and 0.1% Bromfenac sodium hydrate ophthalmic solution on prevention of cystoid macular edema after cataract surgery.
Methods
A retrospective chart review of 349 patients who received phacoemulsification with intraocular lens implantation in Severance Hospital from July 2013 to January 2016 was performed. In these patients, 192 eyes received 1% Prednisolone acetate ophthalmic solution, and 157 eyes were treated with topical 0.1% Bromfenac sodium hydrate ophthalmic solution. The incidence and severity of cystoid macular edema (CME) were evaluated by retinal foveal thickness on optical coherence tomography for patients who showed best corrected visual acuity (BCVA) less than 0.5 (log MAR ≥ 0.3).
Results
There was no significant difference between the two groups in age (p = 0.708), sex (p = 0.977), or the side of operated eye (p = 0.443). The two groups showed BCVA 0.04 ± 0.09 (Steroid group) and 0.03 ± 0.07 (nonsteroidal anti-inflammatory drug [NSAID] group) at 1 month after the surgery and the difference was not significant (p = 0.947). One eye in the topical steroid group had cystoid macular edema, and 3 eyes in the steroid group showed elevated intraocular pressure (IOP) over 30 mm Hg. There were no IOP elevations or macular edema in the NSAID group.
Conclusions
The results showed that 0.1% Bromfenac sodium hydrate ophthalmic solution had a similar effect to 1% Prednisolone acetate ophthalmic solution on preventing CME after cataract surgery. This indicates that topical NSAID can be considered along with topical steroids in order to prevent CME after cataract surgery.
References
1. Drolsum L, Haaskjold E. Causes of decreased visual acuity after cataract extraction. J Cataract Refract Surg. 1995; 21:59–63.
2. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998; 96:557–634.
3. Asahi MG, Bobarnac Dogaru GL, Onishi SM, Gallemore RP. Strong topical steroid, NSAID, and carbonic anhydrase inhibitor cocktail for treatment of cystoid macular edema. Int Med Case Rep J. 2015; 8:305–12.
4. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002; 47(Suppl 1):S203–18.
5. McColgin AZ, Heier JS. Control of intraocular inflammation abdominal with cataract surgery. Curr Opin Ophthalmol. 2000; 11:3–6.
6. Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular abdominal response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol. 1993; 9:157–65.
7. Clark AF, Wilson K, de Kater AW, et al. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci. 1995; 36:478–89.
8. Miyake K. Prevention of cystoid macular edema after lens abdominal by topical indomethacin (I). A preliminary report. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1977; 203:81–8.
9. Miyake K, Sugiyama S, Norimatsu I, Ozawa T. Prevention of abdominal macular edema after lens extraction by topical indomethacin (III) radioimmunoassay measurement of prostaglandins in the aqueous during and after lens extraction procedures. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1978; 209:83–8.
10. Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The abdominal of a meta-analysis. Ophthalmology. 1998; 105:397–405.
11. Wittpenn JR, Silverstein S, Heier J, et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008; 146:554–60.
12. Heier JS, Topping TM, Baumann W, et al. Ketorolac versus abdominal versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000; 107:2034–8. discussion 2039.
13. O'Brien TP. Emerging guidelines for use of NSAID therapy to opti-mize cataract surgery patient care. Curr Med Res Opin. 2005; 21:1131–7.
14. Kessel L, Tendal B, Jørgensen KJ, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal an-ti-inflammatory eye drops: a systematic review. Ophthalmology. 2014; 121:1915–24.
15. Wielders LH, Lambermont VA, Schouten JS, et al. Prevention of cystoid macular edema after cataract surgery in nondiabetic and abdominal patients: a systematic review and meta-analysis. Am J Ophthalmol. 2015; 160:968–81.e33.
16. Bélair ML, Kim SJ, Thorne JE, et al. Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis abdominal optical coherence tomography. Am J Ophthalmol. 2009; 148:128–35.e2.
17. Kim SJ, Bressler NM. Optical coherence tomography and cataract surgery. Curr Opin Ophthalmol. 2009; 20:46–51.
18. Kraff MC, Sanders DR, Jampol LM, et al. Prophylaxis of abdominal cystoid macular edema with topical indomethacin. Ophthalmology. 1982; 89:885–90.
19. Asano S, Miyake K, Ota I, et al. Reducing angiographic cystoid macular edema and blood–aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. J Cataract Refract Surg. 2008; 34:57–63.
20. Nussenblatt RB, Kaufman SC, Palestine AG, et al. Macular abdominal and visual acuity. Measurement in patients with cystoid abdominal edema. Ophthalmology. 1987; 94:1134–9.
21. Mentes J, Erakgun T, Afrashi F, Kerci G. Incidence of cystoid abdominal edema after uncomplicated phacoemulsification. Ophthalmologica. 2003; 217:408–12.
22. Congdon NG, Schein OD, von Kulajta P, et al. Corneal abdominal associated with topical ophthalmic use of nonsteroidal antiabdominal drugs. J Cataract Refract Surg. 2001; 27:622–31.
Table 1.
Group (n, %) |
p-value | ||
---|---|---|---|
Steroid | NSAID | ||
No. of eyes | 192 | 157 | |
Age (years) | 67.11 ± 11.13 | 67.10 ± 11.51 | 0.708* |
Sex | |||
Male | 80 (41.67) | 66 (42.04) | 0.977† |
Female | 112 (58.33) | 91 (57.96) | |
Laterality | |||
Right | 88 (45.83) | 78 (49.68) | 0.443† |
Left | 104 (54.17) | 79 (50.32) | |
Preop. BCVA (log MAR) | 0.46 ± 0.50 | 0.38 ± 0.40 | 0.158* |
Preop. IOP (mm Hg) | 14.13 ± 3.09 | 14.31 ± 2.65 | 0.411* |
Table 2.
Variables |
Group (n, %) |
p-value* | |
---|---|---|---|
Steroid | NSAID | ||
IOP spike | 3 (1.57) | 0 | 0.115 |
Cystoid macular edema | 1 (0.52) | 0 | 0.365 |
Keratopathy | 0 | 1 (0.64) | 0.270 |
BRVO | 1 (0.52) | 0 | 0.365 |